Not Signed In - BioMarin Announces Results From Phase 2 Clinical Study Of 6R-BH4 In Poorly Controlled Hypertension
Wed, 21 Feb 2007 08:00 AM EST
... BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results from its Phase 2a placebo-controlled double-blind study of 6R-BH4 in patients with poorly controlled hypertension. Results demonstrate that there was no statistically significant or clinically meaningful effect of 6R-BH4 on any efficacy or safety parameter measured, relative to placebo. [click link for full article] ...
Related Topics
- Clinical Trials
- Pulmonary Hypertension
- Intracranial Hypertension
- Hypertension
- Pharmacology
- Psychopharmacology
- Poorly aligned teeth
- Tetrahydrobiopterin deficiency
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Health psychology
- Retinopathy
- Radiation Studies
- Benign Intracranial Hypertension
- Hypnotherapy
- Epidemiology
- Clinical Laboratory Improvement Amendments
- Depression
email this page
print this page
bookmark this page
feedback on this page
